Next 10 |
Humacyte raises $245M gross proceeds Combined company is expected to begin trading on the Nasdaq Global Select Market® under “HUMA” and “HUMAW” on August 27, 2021 Company well-positioned to deliver on promise of regenerative tissue HAV ...
Gainers: Good Works Acquisition (NASDAQ:GWAC) +13%. LGL Systems Acquisition (NYSE:DFNS) +7%. KE Holdings (NYSE:BEKE) +6%. Alpha Healthcare Acquisition (NASDAQ:AHAC) +6%. Losers: SelectQuote (NYSE:SLQT) -43%. Sentage Holdings (NASDAQ:SNTG) -21%. Investcorp Credit Management (NASDAQ:ICMB) -14%....
Alpha Healthcare Acquisition (NASDAQ:AHAC) announces business combination with Humacyte, a clinical-stage biotechnology platform company. Shareholders approved the business combination proposal with 99.5% votes in favor of the approximately 61.6% of AHAC votes cast at the meeting. The co...
NEW YORK and DURHAM, N.C., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) (“AHAC”), a special purpose acquisition company, today announced that its stockholders voted to approve the previously announced business combination with Humacyte, I...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Appoints proven commercial leader B.J. Scheessele as Chief Commercial Officer In-house Durham, N.C. facility is operational and supplying clinical trial material produced in commercial-scale manufacturing system Company’s proprietary modular manufacturing systems ...
Data demonstrate biovascular pancreas may have the potential to provide an effective and safe method for pancreatic islet cell transplantation for the treatment of type 1 diabetes Data published in the Journal of Tissue Engineering DURHAM, N.C., Aug. 11, 2021 (GLOBE NEWS...
Special shareholder meeting to approve, among other items, the proposed business combination with Humacyte, Inc. to be held August 24, 2021, at 10:00 a.m. EDT Shareholders as of the close of business on July 21, 2021, should vote their AHAC shares, no matter how many shares ...
DURHAM, N.C., July 22, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announces that Laura Niklason, M.D., Ph.D., Chief Executive Officer, delivered an invited ...
PAVmed's main commercial-stage product, EsoCheck/EsoGuard, is a life-saving product addressing a $25bil market and is supported by Exact Sciences founder Stanley Lapidus. PAVmed's second commercial-stage product, CarpX, is a minimally invasive tool to conduct carpel tunnel surgery and...
News, Short Squeeze, Breakout and More Instantly...
Humacyte Inc Com Company Name:
AHAC Stock Symbol:
NASDAQ Market:
Humacyte raises $245M gross proceeds Combined company is expected to begin trading on the Nasdaq Global Select Market® under “HUMA” and “HUMAW” on August 27, 2021 Company well-positioned to deliver on promise of regenerative tissue HAV ...
NEW YORK and DURHAM, N.C., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) (“AHAC”), a special purpose acquisition company, today announced that its stockholders voted to approve the previously announced business combination with Humacyte, I...
Appoints proven commercial leader B.J. Scheessele as Chief Commercial Officer In-house Durham, N.C. facility is operational and supplying clinical trial material produced in commercial-scale manufacturing system Company’s proprietary modular manufacturing systems ...